| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 7, 2019To Assess the Potential of Non-Opioid Treatment Options for Chronic Pain, Study Evaluates Pain Relief, Patient Function and Satisfaction
DUBLIN and LAS VEGAS - May 7, 2019 - Medtronic plc (NYSE:MDT) today announced primary endpoint (3-month) results of the Vectors Post Market Clinical Study that demonstrated effective pain relief...
-
Apr 30, 2019System Offers New Options for Improving Outcomes in Treating Stroke; World's Second-Leading Cause of Death, Third-Leading Cause of Disability
DUBLIN - April 30, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device - and its first use in patients for the treatment of acute...
-
Mar 17, 2019Late-Breaking Trial Results Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine
DUBLIN and NEW ORLEANS - March 17, 2019 - Medtronic plc (NYSE:MDT) today announced results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT), which...
-
Mar 16, 2019Less Invasive Evolut™ Transcatheter Aortic Valve Replacement (TAVR) System Successful in Clinical Trial When Compared to Open Heart Surgery in Healthier Aortic Stenosis Patients
DUBLIN and NEW ORLEANS – March 16, 2019 – Medtronic plc (NYSE:MDT) today announced first-ever clinical data from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™...
-
Mar 8, 2019Board Authorizes $6 Billion for Share Repurchases
DUBLIN - March 8, 2018 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 fourth quarter cash dividend of $0.50 per ordinary share, representing a 9 percent...